Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "strong sell" to "hold".
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR [Yahoo! Finance]
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? [Yahoo! Finance]
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [Yahoo! Finance]
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [TheStreet.com]